TORONTO, May 14 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) today announced results for the second quarter ended March 31, 2008, and outlined steps that have been taken in implementing its strategic business plan. “We have made significant progress in moving VIRUSMAX(TM) and Urokinase into the market since the first quarter, and we expect to reach important milestones with SST(TM)in the coming months. Our base Virology business continues to support our pipeline development activities with strong cash flows from this division,” said Microbix CEO William J. Gastle.
